0001209191-22-020984.txt : 20220324
0001209191-22-020984.hdr.sgml : 20220324
20220324192404
ACCESSION NUMBER: 0001209191-22-020984
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220322
FILED AS OF DATE: 20220324
DATE AS OF CHANGE: 20220324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schroeder Thilo
CENTRAL INDEX KEY: 0001776412
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39219
FILM NUMBER: 22767885
MAIL ADDRESS:
STREET 1: C/O NEXTECH INVEST LTD.
STREET 2: BAHNHOFSTRASSE 18
CITY: ZURICH
STATE: V8
ZIP: 8001
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revolution Medicines, Inc.
CENTRAL INDEX KEY: 0001628171
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472029180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 SAGINAW DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 415-766-3638
MAIL ADDRESS:
STREET 1: 700 SAGINAW DR
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-22
0
0001628171
Revolution Medicines, Inc.
RVMD
0001776412
Schroeder Thilo
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
REDWOOD CITY
CA
94063
1
0
0
0
Common Stock
2022-03-22
4
P
0
5440
22.15
A
701666
I
By Nextech Crossover I SCSP
Common Stock
2022-03-22
4
P
0
71186
23.18
A
772852
I
By Nextech Crossover I SCSP
Common Stock
2022-03-22
4
P
0
53501
23.69
A
826353
I
By Nextech Crossover I SCSP
Common Stock
2022-03-23
4
P
0
37708
23.61
A
864061
I
By Nextech Crossover I SCSP
Common Stock
2022-03-23
4
P
0
15410
23.99
A
879471
I
By Nextech Crossover I SCSP
Common Stock
2022-03-24
4
P
0
49119
24.26
A
928590
I
By Nextech Crossover I SCSP
Common Stock
2668214
I
By Nextech V Oncology S.C.S., SICAV-SIF
Common Stock
300000
I
By Nextech VI Oncology SCSp
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.49 to $22.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.50 to $23.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $23.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.88 to $23.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.85 to $24.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares,
except to the extent of any pecuniary interest therein.
Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares,
except to the extent of any pecuniary interest therein.
/s/ Darren DeStefano, Attorney-in-Fact
2022-03-24